GlaxoSmithKline’s experimental TB vaccine has shown that it could help prevent the disease, but further research is needed to identify patients with the strongest response.
Alexion is preparing filings in major markets for its rare disease drug Soliris in a new indication after a positive readout in a rare neurological disease.
Allergan and Sosei’s experimental Alzheimer’s medicine has run into trouble – the companies have called a halt to trials after an unexpected toxicology finding in an animal study.<
Novo Nordisk is laying off 400 people in Denmark and China so it can overhaul its R&D and speed up the expansion and diversification of products for serious chronic diseases.